Bial Pharmaceuticals and Portuguese state sign 37 million contract for scientific research -
Bial and the Portuguese state today signed an investment contract worth 37.4 million euros for scientific research in the areas of the central nervous and cardiovascular systems in Trofa, Porto, Bial said.
Bial's investment agreement with the state extends until 2018 and comes after the government has approved tax benefits for industrial investments approved by the Council of Ministers last December.
«The investments now contracted are intended to increase the company's research and development in the areas of the central nervous and cardiovascular systems», reads a statement sent to the news agency " Lusa ”.
At the Trofa R & D center there are about 100 researchers from nine nationalities studying and investigating new treatment solutions in those two areas.
The pharmaceutical company Bial develops a research activity, having synthesized 12 thousand molecules in the last 25 years and patented more than 1300 brands. Bial holds the only medicines developed in Portugal and are in commercialization in dozens of countries.
The company's first antiepileptic drug, Zebinix, is now approved in 43 countries and is already marketed in several European countries and the United States of America.
Bial's second research drug for the treatment of Parkinson's disease - Ongentys - is on sale in the UK and Germany and is expected to be introduced in other European countries this year, the company said.
The signing of the investment agreement between Bial and the business entity of the State Agency for Investment and Foreign Trade of Portugal (AICEP) is part of the system of incentives for research and development of the PT 2020 - Community funds destined for Portugal By 2020 - and includes the interventions of the prime minister and the executive director of Bial.
Source: "Netfarma" website and author on January 23, 2017